Navigation Links
Tobira Therapeutics Inc. Announces Senior Management Team
Date:6/30/2008

- Senior management team possessing over 130 years of cumulative expertise

-

PRINCETON, N.J. and SAN DIEGO, June 30 /PRNewswire/ -- Tobira Therapeutics Inc., a clinical stage biotechnology company committed to the research and product discovery against life-threatening and life-altering infectious diseases, today announced the organization of the company's senior management team. Tobira Therapeutics has been led since its inception in 2006 by James Sapirstein, RPh, MBA as Chief Executive Officer and President. Joining James is Sandra Palleja, MD, Executive Vice-President and Chief Medical Officer, Angeline Shashlo, RPh, Senior Vice-President Regulatory Affairs and Quality Assurance, and Jay Rheingold, PhD, Vice-President Chemistry Manufacturing and Controls. These additions continue to build the management team with world-class pharmaceutical development experts. "With this senior management team Tobira Therapeutics has more than 130 years of combined pharmaceutical experience, with the majority focused in biotech companies or HIV compounds. We are perfectly positioned to bring novel molecules to market that will play an important role in the treatment of HIV infection".

Dr. Palleja is the Chief Medical Officer, responsible for the overall clinical development of the Tobira Therapeutics portfolio. Sandra joined Tobira from Shionogi USA, where she lead numerous clinical programs as Vice President of Clinical Development in several therapeutic categories including an HIV joint venture with GSK. Prior to her years at Shionogi, Sandra gained additional experience from both Triangle Pharmaceutics and Hoffman-LaRoche, where she helped develop a variety of antivirals for HIV and hepatitis including FTC, DAPD, ganciclovir, and saquinavir. Prior to her career in industry, she was the Director of the Infectious Diseases Clinic at St. Vincent's Hospital and Medical Center of New York City during the mid to late 90's. Pri
'/>"/>

SOURCE Tobira Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Duska Therapeutics Obtains Standard & Poors Listing
2. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
3. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
4. Sirion Therapeutics Announces FDA Approval of Durezol(TM) for Treatment of Postoperative Ocular Inflammation and Pain
5. Commercial Launch of Lexiscan(TM) (Regadenoson) Injection Triggers $10 Million Milestone Payment from TPG-Axon Capital to CV Therapeutics
6. Barrier Therapeutics to Merge Into Stiefel Laboratories
7. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
8. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
9. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
10. Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt
11. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015  Turing Pharmaceuticals AG announced ... Oreste Salinas , MD, MSc,  has joined the ... Dr. Salinas, who holds a medical degree ... a record of significant accomplishments in the pharmaceutical ... Dr. Salinas has played a leadership role ...
(Date:6/1/2015)... Korea , June 1, 2015 This ... (GCBT) kicked off construction today on its biopharmaceutical facility ... Campus. The CA$315 million project represents one of the ... in the biopharmaceutical industry, giving place to ... albumin manufacturing plant in Canada . ...
(Date:6/1/2015)... June 1, 2015 GenomeDx Biosciences ... analysis platform, successfully classified various subtypes of ... of certain biomarkers, including one type associated ... unique genomic signature has potential as a ... chemotherapy in patients with muscle-invasive bladder cancers ...
(Date:6/1/2015)... , June 1, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... March 31, 2015.  Biorem,s complete 2015 first quarter financial statements and ... Financial Summary:Three-months ended March 31,(in CDN$,000 except per share ... 4,689 , 1,974 Gross profit , 1,531 ... Net earnings (loss) , 528 , (531) Basic ...
Breaking Biology Technology:Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3Green Cross Biotherapeutics Kicks Off Construction in Montreal 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Biorem Reports Increased Revenues and Earnings for First Quarter 2Biorem Reports Increased Revenues and Earnings for First Quarter 3
... May 12 Aton Pharma, Inc., a global,specialty ... a,distribution agreement with Meizler Biopharma S/A to commercialize,CUPRIMINE(R) ... in,Brazil, and Meizler is working to obtain regulatory ... medically essential products, and Aton is,committed to making ...
... Poised to Impact Lung Cancer Care, ST. ... medical,device start-up company, has secured $4.75M in venture ... IG4 delivery system for minimally,invasive biopsy and ablation ... and was joined by Advantage Capital Partners and ...
... (NYSE:,CVD) today announced that it will present at the ... 2008 at 10:30 am ET. Investors may,access a live ... order to,register and download any necessary software, please log ... New Jersey, is one of the,world,s largest and most ...
Cached Biology Technology:Aton Pharma Announces Distribution Partnership in Brazil 2Veran Medical Technologies Secures $4.75M in First Institutional Funding 2
(Date:5/11/2015)... , May 11, 2015  Through a well-rounded UAS ... had a strong showing at AUVSI,s Unmanned 2015 ... representatives of Ohio,s UAS industry met ... abroad from all points along the UAS ecosystem. ... Coalition,s (DDC) Vice President for Aerospace Rich Knoll . ...
(Date:5/6/2015)... 6, 2015 LifeBEAM, a developer of bio-sensing ... announced today that they will expand their partnership in ... bio-sensing cycling helmet and the first joint project between ... colors in order to give cyclists more style choices ... LifeBEAM and Lazer announced their plan to release a ...
(Date:4/21/2015)... 2015 High crime rate, ... boosting access control systems market in Saudi ... recently published report by TechSci Research " Saudi Arabia Access ... control systems market in Saudi Arabia ... access control systems market in the Kingdom is growing ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3
... patients was given potentially hazardous medication during 2007. That ... and her co-authors in the current issue of the ... 2012; 109[5]: 69-75). Giving certain medical drug ... drug effects, and for this reason experts describe them ...
... women with a previous history of cardiovascular pathologies seem ... of supplementation. The research is published in detail in ... some studies have suggested that supplementation with B vitamins ... randomised clinical trials conducted internationally in recent years remain ...
... senior scientist and director of the Marine Biological Laboratory ... Antarctic Program Blue Ribbon Panel. The 12-member panel, ... the White House Office of Science and Technology Policy ... is tasked with examining the status and capabilities of ...
Cached Biology News:Vitamin B and omega-3 supplementation and cancer: New data 2MBL's Hugh Ducklow appointed to Antarctic Blue Ribbon Panel 2
... The Caliper Sciclone ALH 3000 workstation ... diagnostic applications, from Genomic and Proteomic Sample ... Assays. The modular design of the ... options and accessories to perfectly meet the ...
... The Sciclone inL10 Workstation from Caliper represents ... offering for the first time the ability ... automatically react to changing conditions. In ... in viscosity due to changes in temperature, ...
ID clarifier: non-treated with lid...
... Workstation fully automates pharmaceutical sample preparation ... sample transfer, mixing and dilutions. Capabilities ... detection. The Prelude performs these functions ... Part 11. The Prelude performs ...
Biology Products: